Overview
Minagene's HRR gene testing utilizes tumor and germline matched comprehensive genomic profiling to screen for mutations in homologous recombination repair genes (BRCA1, BRCA2, PALB2, etc.).
Methodology
Tissue specimens undergo nucleic acid extraction and library preparation for hybrid capture-based next generation sequencing of all clinically actionable exons/introns across 45+ key HRR genes. Proprietary bioinformatics analyze both somatic and constitutional alterations to determine eligibility for PARP and other targeted therapies.
Key Highlights of Minagene’s Homologous Recombination Repair Gene Testing
Key Highlights of Minagene’s Homologous Recombination
-Identifies defective HRR signature regardless of cancer type
-Determines germline/somatic origin of pathogenic variants
-Assesses complex genomic profiles for synthetic lethality
-Supports treatment with PARP inhibitors, platinum agents
-Improves outcomes through precision therapy selection
By using an unbiased multi-gene approach, Minagene’s solution comprehensively interrogates the HRR pathway. Matched tumor-normal analysis guides definitive targeted therapy and enrollment in investigative clinical trials.
When to Consider Minagene’s Homologous Recombination Repair Gene Testing
Physicians should order HRR testing for advanced solid tumors refractory to standard therapies, particularly ovarian and breast cancers evaluated for PARP inhibitors.
